Incentive structure: Big pharma ... or companies fail. Only a tiny few biotech innovations will become globally impactful successes. Further, it can take 10-20 years for innovations to pay off.

BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MTP ... deal struck with AstraZeneca in December, with the UK big pharma company signing a drug development deal worth up to $1 ...

An Enquirer analysis found that doctors, nurses and other practitioners received $136 million from pharma and biotech ...

At nearly 750,000 entries, the dataset of transactions between companies and medical practitioners in Cincinnati was ...

Would the Trump administration's recently proposed drug pricing reforms hurt the biotech sector more than pharma? Seeking ...

In an effort to become more nimble, some companies, like Bayer Pharmaceutical, are getting rid of middle managers.

Given that Piramal’s CDMO customer-mix is skewed towards big pharma and emerging biopharma, with only 39% exposure to generics, the company is at risk if Trump’s drug price order goes through.

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

Legal action had already been taken against four pharmaceutical companies caught overcharging, with action approved by the cabinet. He added that provincial health departments had been asked to ...

More importantly to consumers who have privacy concerns during the proceedings, the pharmaceutical company promised to adhere to 23andMe's existing privacy policy, saying it will "prioritize the ...